{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:40:29Z","timestamp":1782632429269,"version":"3.54.5"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jns.2023.122852","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T14:14:31Z","timestamp":1703081671000},"page":"122852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"456","author":[{"given":"Theodoros","family":"Marantos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdoxia","family":"Kyriazopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Voumvourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsiodras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2023.122852_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"(b). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/WCO.0000000000001066","article-title":"Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations","volume":"35","author":"Pugliatti","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10654-019-00595-2","article-title":"Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway","volume":"35","author":"Ghaderi","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.jns.2023.122852_bb0020","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/jech-2011-200168","article-title":"Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses","volume":"66","author":"Wotton","year":"2012","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.jns.2023.122852_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"10.1016\/j.jns.2023.122852_bb0030","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"(a). Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2023.122852_bb0035","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.jns.2023.122852_bb0040","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.jns.2023.122852_bb0045","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrica."},{"key":"10.1016\/j.jns.2023.122852_bb0050","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO;2-A","article-title":"A likelihood approach to meta-analysis with random effects","volume":"15","author":"Hardy","year":"1996","journal-title":"Stat. Med."},{"key":"10.1016\/j.jns.2023.122852_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"10.1016\/j.jns.2023.122852_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jns.2023.122852_bb0065","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics."},{"key":"10.1016\/j.jns.2023.122852_bib411","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. Available from: http:\/\/www.r-project.org\/index.html [Accessed 25 January 2021]."},{"key":"10.1016\/j.jns.2023.122852_bb0070","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"(b). COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2023.122852_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577746","article-title":"(a). Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: up to 6 months cross-sectional study","volume":"361","author":"Achiron","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2023.122852_bb0080","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1016\/j.vaccine.2021.09.030","article-title":"Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV","volume":"39","author":"Ali Sahraian","year":"2021","journal-title":"Vaccine."},{"key":"10.1016\/j.jns.2023.122852_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103028","article-title":"Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis","volume":"52","author":"Allen-Philbey","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0090","article-title":"Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America","volume":"7","author":"Alonso","year":"2021","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"10.1016\/j.jns.2023.122852_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107374","article-title":"COVID-19 vaccination in people with multiple sclerosis, real-life experience","volume":"220","author":"Alroughani","year":"2022","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2023.122852_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104582","article-title":"Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: a monocentric experience","volume":"72","author":"Bertozzi","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0105","article-title":"COVID-19 vaccination reactogenicity in persons with multiple sclerosis","volume":"9","author":"Briggs","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.jns.2023.122852_bb0110","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/jamaneurol.2021.3599","article-title":"Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab","volume":"78","author":"Brill","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0115","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/ene.15265","article-title":"Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: an Austrian prospective multicenter cohort study","volume":"29","author":"Bsteh","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13311-021-01165-9","article-title":"Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies","volume":"19","author":"Capone","year":"2022","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.jns.2023.122852_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103690","article-title":"Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis","volume":"59","author":"Ciampi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0130","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaneurol.2021.3609","article-title":"Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis","volume":"78","author":"Disanto","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120155","article-title":"COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose","volume":"434","author":"Dreyer-Alster","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2023.122852_bb0140","article-title":"SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: gender-specific results from a longitudinal observational study","volume":"22","author":"Frahm","year":"2022","journal-title":"Lancet Reg Health Eur."},{"key":"10.1016\/j.jns.2023.122852_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103636","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBioMedicine."},{"key":"10.1016\/j.jns.2023.122852_bb0150","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1007\/s00415-022-11142-7","article-title":"Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study","volume":"269","author":"Giannoccaro","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071397","article-title":"Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study","volume":"13","author":"Hitchon","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jns.2023.122852_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103382","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab","volume":"57","author":"Katz","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103708","article-title":"Safety of Sinopharm vaccine for people with multiple sclerosis: study of adverse reactions and disease activity","volume":"61","author":"Kavosh","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104167","article-title":"Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"68","author":"Kong","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/jnnp-2021-327612","article-title":"Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations","volume":"94","author":"K\u00f6nig","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2023.122852_bb0180","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.26309","article-title":"B Cell depletion and SARS-CoV-2 vaccine responses in neuroimmunologic patients","volume":"91","author":"Kornek","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0185","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1111\/ene.15028","article-title":"Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel","volume":"28","author":"Lotan","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0190","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1007\/s00415-022-11003-3","article-title":"Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis","volume":"269","author":"Mariottini","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103486","article-title":"Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies","volume":"58","author":"Ozakbas","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103712","article-title":"A one year follow of patients with multiple sclerosis during COVID-19 pandemic: a cross-sectional study in Qom province, Iran","volume":"60","author":"Paybast","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.781843","article-title":"Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients","volume":"12","author":"Pitzalis","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2023.122852_bb0210","first-page":"358","article-title":"Serological response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina","volume":"83","author":"Rojas","year":"2023","journal-title":"Medicina (B Aires)."},{"key":"10.1016\/j.jns.2023.122852_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine."},{"key":"10.1016\/j.jns.2023.122852_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104707","article-title":"Experiences of persons with multiple sclerosis with the Covid-19 vaccination: a cross-sectional study of the Swiss Multiple Sclerosis Registry","volume":"74","author":"Staniki\u0107","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.26251","article-title":"COVID-19 vaccine response in people with multiple sclerosis","volume":"91","author":"Tallantyre","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104120","article-title":"Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis","volume":"68","author":"Tavazzi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0235","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11497","article-title":"Factors associated with serological response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with rituximab","volume":"5","author":"Tolf","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jns.2023.122852_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102984","article-title":"Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations","volume":"135","author":"van Dam","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jns.2023.122852_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103856","article-title":"Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies","volume":"63","author":"Wallach","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0250","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.0b013e31829e6fbf","article-title":"Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis","volume":"81","author":"Bar-Or","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2023.122852_bb0255","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2023.122852_bb0260","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2023.122852_bb0265","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cns.13034","article-title":"Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies","volume":"25","author":"Metze","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jns.2023.122852_bb0270","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458513513970","article-title":"Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study","volume":"20","author":"Olberg","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2023.122852_bb0275","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102859","article-title":"Seroconversion rate following HBV vaccination in clinical practice: the role of age and DMT treatment","volume":"50","author":"Faustino","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102906","article-title":"Rabies vaccination and multiple sclerosis relapse: a retrospective cohort study","volume":"51","author":"Huttner","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0290","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2014.03.035","article-title":"Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis","volume":"341","author":"Kaufman","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2023.122852_bb0295","article-title":"Immune response to vaccines is maintained in patients treated with dimethyl fumarate","volume":"5","author":"von Hehn","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.jns.2023.122852_bb0300","doi-asserted-by":"crossref","first-page":"e908","DOI":"10.1212\/WNL.0000000000008012","article-title":"A large case-control study on vaccination as risk factor for multiple sclerosis","volume":"93","author":"Hapfelmeier","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2023.122852_bb0305","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jns.2023.122852_bb0310","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0315","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3201\/eid2407.161783","article-title":"Registry cohort study to determine risk for multiple sclerosis after vaccination for pandemic influenza a(H1N1) with Arepanrix, Manitoba, Canada","volume":"24","author":"Mahmud","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jns.2023.122852_bb0320","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.vaccine.2019.02.046","article-title":"Hepatitis B vaccination and central demyelination - history, description and observed\/expected analyses of 624 cases reported to the French pharmacovigilance over a 20-year period","volume":"37","author":"Mouchet","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.jns.2023.122852_bb0325","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1007\/s00415-023-11822-y","article-title":"Association between vaccination and the risk of central demyelination: results from a case-referent study","volume":"270","author":"Grimaldi-Bensouda","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0330","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000991","article-title":"Vaccine hesitancy in patients with multiple sclerosis: preparing for the SARS-CoV-2 vaccination challenge","volume":"8","author":"Diem","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.jns.2023.122852_bb0335","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis: a systematic review","volume":"264","author":"Mailand","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718895","article-title":"Tetravalent influenza vaccine is not associated with neuroaxonal damage in multiple sclerosis patients","volume":"12","author":"Moser","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2023.122852_bb0345","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/13524585221150881","article-title":"Safety of COVID-19 vaccines in multiple sclerosis: a systematic review and meta-analysis","volume":"29","author":"Stefanou","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2023.122852_bb0350","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of Neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2023.122852_bb0355","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.msard.2019.04.004","article-title":"Immunization and multiple sclerosis: recommendations from the French multiple sclerosis society","volume":"31","author":"Lebrun","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0360","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.nrl.2020.02.006","article-title":"Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement","volume":"36","author":"Otero-Romero","year":"2021","journal-title":"Neurologia (Engl Ed)."},{"key":"10.1016\/j.jns.2023.122852_bb0365","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/ene.15809","article-title":"European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: improving immunization strategies in the era of highly active immunotherapeutic drugs","volume":"30","author":"Otero-Romero","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0370","first-page":"CD015021","article-title":"Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review","volume":"8","author":"Kreuzberger","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2023.122852_bb0375","doi-asserted-by":"crossref","first-page":"1194671","DOI":"10.3389\/fimmu.2023.1194671","article-title":"Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study","volume":"14","author":"Alfonso-Dunn","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2023.122852_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103157","article-title":"T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers","volume":"55","author":"Iannetta","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2023.122852_bb0385","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/13524585221134216","article-title":"T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy","volume":"29","author":"Reder","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2023.122852_bb0390","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jns.2023.122852_bb0395","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jns.2023.122852_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jns.2023.122852_bb0405","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/acn3.51342","article-title":"Multiple sclerosis, rituximab, and COVID-19","volume":"8","author":"Langer-Gould","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2023.122852_bb0410","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36697","article-title":"Rituximab infusion timing, cumulative dose, and hospitalization for COVID-19 in persons with multiple sclerosis in Sweden","volume":"4","author":"McKay","year":"2021","journal-title":"JAMA Netw. Open"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23023146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23023146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:05:15Z","timestamp":1758384315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X23023146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":83,"alternative-id":["S0022510X23023146"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2023.122852","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2023.122852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122852"}}